ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Business Wire
-- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner ---- Proven track record with largest number of Competitive Generic Therapy (CGT) approvals ---- Deep pipeline with a focus on niche opportunities, including 505(b)(2) candidates in Oncology and Hypertension ---- Pro-forma September 30, 2021 YTD revenues are $202.5 million and non-GAAP EBITDA $66.6 million ---- Founders Samy Shanmugam and Chad Gassert to join Executive Team and Mr. Shanmugam to join Board of Directors ---- Immediately accretive to Adjusted non-GAAP earnings per share ---- New capital structure in place -- BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization c
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $77.00 price target on the stock.MarketBeat
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ETGlobeNewswire
- GSK Announces FDA Acceptance of New Meningococcal Jab BLA [Yahoo! Finance]Yahoo! Finance
- Why ANI (ANIP) is Poised to Beat Earnings Estimates Again [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 2/29/24 - Beat
ANIP
Sec Filings
- 4/22/24 - Form 4
- 4/19/24 - Form 144
- 4/18/24 - Form 144
- ANIP's page on the SEC website